FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588336857> ?p ?o ?g. }

• W2588336857 abstract "AbstractImmunotherapeutic concepts for brain tumors have been hampered by lack of selective measures to target the CNS and lack of truly tumor-specific antigens. But the concept of an immune privileged CNS has to be questioned due to survey of the brain by specific T-cells, CNS autoimmunity and presence of lymphatics. As tumor-specific antigens, mutated antigens have come into focus for all tumor entities. Mutations in the gene for isocitrate dehydrogenase 1 frequently occur in diffuse gliomas, mostly astrocytomas, resulting in a point mutation (mostly IDH1R132H). IDH1R132H is an ideal tumor-specific antigen, because it is tumor-specific, homogenously expressed and considered a driving mutation in glioma. Preclinical studies have shown that mutation-specific Th cell responses spontaneously occur in patients with IDH1-mutated gliomas and that a peptide vaccine encoding IDH1R132H is therapeutic in a humanized mouse tumor model.Based on these data we have initiated a multicenter, first-in-man, phase I clinical vaccine trial, which is planned to enroll 39 patients with newly diagnosed malignant IDH1R132H+ astrocytomas at eight German sites: NOA-16 (NCT02454634). The vaccine is made of an IDH1R132H peptide emulsified in mineral oil and administered with topical imiquimod. Vaccination is implemented into primary standard therapy. Primary end points are safety and immunogenicity as measured by IDH1R132H-specific antibodies and T cell responses. As of March 2016, 13 patients have been enrolled in the trial; no severe adverse events have been reported.We report here on 3 patients treated with the vaccine on a compassionate use basis. No patient experienced a regime-limiting toxicity as defined in the trial protocol. Two patients received all 8 doses of the vaccine; both developed IDH1-specific antibody responses, which were mutation-specific early after vaccination. Of these, one patient developed a vaccination-induced mutation-specific cellular response. The second patient had a high baseline mutation-specific T cell response, which was temporarily boosted by the vaccine. IFN-γ catch assays from PBMCs of this patient revealed a Th cell-mediated response. To identify and clone IDH1R132H-specific TCR(s) for adoptive T cell therapy, single T cells from this patient specifically responding to IDH1R132H were sorted and subjected to TCR sequencing. 11 TCRs have been identified so far and will be cloned and validated.In summary, we demonstrate for the first time the induction of a mutation-specific humoral and cellular immune response to the IDH1R132H neoepitope after peptide vaccination of patients with IDH1R132H-mutated gliomas. The ongoing trial will analyze safety and immunogenicity of the vaccine in a defined patient cohort, which also allows for collecting data on therapeutic efficacy." @default.
• W2588336857 created "2017-02-24" @default.
• W2588336857 creator A5010760040 @default.
• W2588336857 creator A5012626247 @default.
• W2588336857 creator A5017514499 @default.
• W2588336857 creator A5017575332 @default.
• W2588336857 creator A5018374375 @default.
• W2588336857 creator A5032035174 @default.
• W2588336857 creator A5063978061 @default.
• W2588336857 creator A5064778456 @default.
• W2588336857 creator A5075617216 @default.
• W2588336857 creator A5080482957 @default.
• W2588336857 date "2016-09-21" @default.
• W2588336857 modified "2023-10-02" @default.
• W2588336857 title "OS2.1 Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas" @default.
• W2588336857 doi "https://doi.org/10.1093/neuonc/now188.011" @default.
• W2588336857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5782511" @default.
• W2588336857 hasPublicationYear "2016" @default.
• W2588336857 type Work @default.
• W2588336857 sameAs 2588336857 @default.
• W2588336857 citedByCount "0" @default.
• W2588336857 crossrefType "journal-article" @default.
• W2588336857 hasAuthorship W2588336857A5010760040 @default.
• W2588336857 hasAuthorship W2588336857A5012626247 @default.
• W2588336857 hasAuthorship W2588336857A5017514499 @default.
• W2588336857 hasAuthorship W2588336857A5017575332 @default.
• W2588336857 hasAuthorship W2588336857A5018374375 @default.
• W2588336857 hasAuthorship W2588336857A5032035174 @default.
• W2588336857 hasAuthorship W2588336857A5063978061 @default.
• W2588336857 hasAuthorship W2588336857A5064778456 @default.
• W2588336857 hasAuthorship W2588336857A5075617216 @default.
• W2588336857 hasAuthorship W2588336857A5080482957 @default.
• W2588336857 hasBestOaLocation W25883368571 @default.
• W2588336857 hasConcept C147483822 @default.
• W2588336857 hasConcept C195616568 @default.
• W2588336857 hasConcept C203014093 @default.
• W2588336857 hasConcept C2776789287 @default.
• W2588336857 hasConcept C2778227246 @default.
• W2588336857 hasConcept C2780868878 @default.
• W2588336857 hasConcept C502942594 @default.
• W2588336857 hasConcept C71924100 @default.
• W2588336857 hasConcept C8891405 @default.
• W2588336857 hasConceptScore W2588336857C147483822 @default.
• W2588336857 hasConceptScore W2588336857C195616568 @default.
• W2588336857 hasConceptScore W2588336857C203014093 @default.
• W2588336857 hasConceptScore W2588336857C2776789287 @default.
• W2588336857 hasConceptScore W2588336857C2778227246 @default.
• W2588336857 hasConceptScore W2588336857C2780868878 @default.
• W2588336857 hasConceptScore W2588336857C502942594 @default.
• W2588336857 hasConceptScore W2588336857C71924100 @default.
• W2588336857 hasConceptScore W2588336857C8891405 @default.
• W2588336857 hasLocation W25883368571 @default.
• W2588336857 hasLocation W25883368572 @default.
• W2588336857 hasOpenAccess W2588336857 @default.
• W2588336857 hasPrimaryLocation W25883368571 @default.
• W2588336857 hasRelatedWork W2047766643 @default.
• W2588336857 hasRelatedWork W2141099036 @default.
• W2588336857 hasRelatedWork W2150114157 @default.
• W2588336857 hasRelatedWork W2155367074 @default.
• W2588336857 hasRelatedWork W2313240446 @default.
• W2588336857 hasRelatedWork W2528582910 @default.
• W2588336857 hasRelatedWork W2546487754 @default.
• W2588336857 hasRelatedWork W2606843215 @default.
• W2588336857 hasRelatedWork W2767052387 @default.
• W2588336857 hasRelatedWork W2796417814 @default.
• W2588336857 hasRelatedWork W2799360291 @default.
• W2588336857 hasRelatedWork W2891414792 @default.
• W2588336857 hasRelatedWork W2914734955 @default.
• W2588336857 hasRelatedWork W2953494693 @default.
• W2588336857 hasRelatedWork W3083654074 @default.
• W2588336857 hasRelatedWork W3091061098 @default.
• W2588336857 hasRelatedWork W3162454602 @default.
• W2588336857 hasRelatedWork W3177732915 @default.
• W2588336857 hasRelatedWork W3182573048 @default.
• W2588336857 hasRelatedWork W3212270814 @default.
• W2588336857 isParatext "false" @default.
• W2588336857 isRetracted "false" @default.
• W2588336857 magId "2588336857" @default.
• W2588336857 workType "article" @default.